A large study reveals no association between APOE and Parkinson's disease

详细信息	查看全文 | 推荐本文 |

• 作者：Monica Federoff ; Belen Jimenez-Rolando ; Michael A. Nalls ; Andrew B. Singleton ; ^{singleta@mail.nih.gov}
• 关键词：Parkinson's disease ; Genetics ; APOE
• 刊名：Neurobiology of Disease
• 出版年：2012
• 期刊代码：80_09699961
• 类别：neu
• 出版时间：May, 2012
• 卷：46
• 期：2
• 页码：389-392
• 文件大小：150 K

摘要

Background

Research focusing on the role of APOE in Parkinson's disease (PD) has been largely inconclusive, creating a broad discrepancy in association studies.

Objective

To elucidate the role of APOE alleles in PD risk by studying a large sample size and controlling for population substructure.

Patients and methods

In total, 3465 case and control samples were genotyped, obtained from the NINDS Neurogenetics repository.

Results

No significant differences in 蔚4 dosages exist between PD cases and controls. The frequency of 蔚4 carriers differed slightly between cases and controls at 24%(580/2412) and 26%(270/1053), respectively. Likewise, mean dosages of APOE 蔚2 were not significantly different between cases and controls. APOE 蔚2 carriers were observed at a frequency of 13.6%(329/2412) among cases and 15%(158/1053) among controls. Logistic regression models evaluating PD as possibly associated with 蔚4 or 蔚2 carrier status and allele dosages yielded no significant results. The mean MMSE score among all PD cases was 28.35 (SD = 2.58) and memory loss was reported in only 11.9%(105/879) of cases. Linear regression models comparing MMSE scores as predicted by 蔚4 or 蔚2 carrier status and allele dosages were not significant.

Conclusions

There is no association between APOE epsilon alleles and Parkinson's disease.